The introduction of new GLP-1 medicines in Kenya marks an important development in the country’s response to obesity, type 2 diabetes and other cardiometabolic conditions. Stowelink Foundation, through its Founder and Chief Executive Officer, Ogweno Stephen, participated in the September 2026 launch of Wegovy and Ozempic by Novo Nordisk, bringing renewed attention to the opportunities and challenges surrounding access to evidence-based obesity treatment in Kenya.
The launch introduced two semaglutide-based medicines into the Kenyan market alongside healthcare professional training and patient-support programmes. Ozempic is indicated for the management of type 2 diabetes, while Wegovy offers a pharmacological treatment option for eligible people living with obesity or overweight accompanied by associated health risks.
For Stowelink Foundation, which works across non-communicable diseases (NCDs), obesity prevention, digital health and public health advocacy, this development represents more than the arrival of new medicines. It opens an important conversation about how Kenya can make advances in obesity treatment safe, affordable and accessible to the people who need them.
The central question is no longer simply whether effective obesity medicines are available. It is whether health systems can create the conditions for equitable access.

Changing How Kenya Understands and Treats Obesity
For many years, obesity has been discussed primarily through the lens of individual behaviour. People living with obesity have often been told to eat less and exercise more, with limited recognition of the biological, environmental, social and commercial factors that influence the disease.
This approach has contributed to stigma and has sometimes prevented people from receiving appropriate medical attention.
However, scientific advances and evolving global health guidance are helping to change the conversation. Obesity is increasingly recognised as a complex, chronic and relapsing disease that requires comprehensive, long-term management.
In December 2025, the World Health Organization published its first guideline on the use of GLP-1 therapies for treating obesity in adults. The guidance acknowledged the potential role of these medicines within comprehensive obesity care while emphasising the importance of long-term management and broader health-system support.
Ogweno Stephen, who contributed to the WHO Guideline Development Group involved in developing this guidance, brings both technical and lived-experience perspectives to the evolving discussion on obesity treatment.
His participation in the Kenyan launch reflects the growing connection between global obesity policy discussions and the practical questions facing African health systems.
For Stowelink Foundation, recognising obesity as a disease must translate into better prevention, accurate public information, reduced stigma and access to appropriate care.
Why the Introduction of Wegovy Matters
The importance of medicines such as Wegovy extends beyond changes in body weight.
GLP-1 therapies act on biological pathways involved in appetite regulation and metabolism. For appropriately selected patients, these medicines can support clinically meaningful weight loss and improve certain metabolic health outcomes.
Obesity is associated with several serious health conditions, including type 2 diabetes, hypertension, cardiovascular disease, sleep apnoea and other complications. Its impact therefore extends beyond an individual’s weight to their overall health, quality of life and need for healthcare services.
The availability of additional treatment options creates opportunities for clinicians and patients to consider more comprehensive approaches to obesity management.
For Kenya, where health systems are already responding to a growing burden of NCDs, strengthening obesity care could contribute to wider efforts to prevent and manage chronic diseases.
However, these benefits depend on appropriate patient assessment, clinical supervision, continued monitoring and access to the broader support needed for long-term disease management.

Understanding the Difference Between Ozempic and Wegovy
As public interest in semaglutide medicines grows, accurate health information becomes increasingly important.
Ozempic and Wegovy contain the same active ingredient, semaglutide, but they have different authorised indications and should not be treated as interchangeable products.
Ozempic is indicated for the management of type 2 diabetes, while Wegovy is specifically indicated for chronic weight management in eligible patients.
This distinction matters because medicines must be prescribed and used according to their approved indications and individual clinical requirements.
GLP-1 therapies are prescription medicines, not cosmetic products or shortcuts to achieving a particular body size. They require assessment by qualified healthcare professionals, appropriate prescribing and ongoing medical supervision.
Stowelink Foundation continues to emphasise the importance of health literacy in helping communities distinguish evidence-based treatment from misinformation, unsafe practices and unrealistic expectations promoted through social media.
As access to obesity medicines expands, public education must grow alongside it.
Why Competition and More Treatment Options Matter
The introduction of Wegovy into Kenya should also encourage a broader discussion about the future of the obesity medicines market.
A healthy treatment ecosystem requires safe, effective and affordable options. Greater competition among manufacturers could potentially expand patient choice and contribute to more accessible pricing over time.
Kenya’s regulatory environment will play an important role in determining which medicines can enter the market and under what conditions.
The Pharmacy and Poisons Board has a responsibility to assess medicines for quality, safety and efficacy and to oversee their registration and authorised use.
The objective should not simply be to increase the number of obesity medicines available. It should be to ensure that patients and healthcare professionals have access to appropriately authorised treatment options supported by reliable evidence and strong regulatory oversight.
For African countries, the development of a competitive and responsible market could become an important part of addressing the growing burden of obesity and related NCDs.
The Role of Generics in Improving Access to Obesity Treatment
One of the most important questions for the future of GLP-1 therapies in Africa is affordability.
Innovative medicines can enter markets at prices that place them beyond the reach of many patients, particularly in countries where healthcare expenditure is heavily dependent on out-of-pocket payments.
If obesity medicines remain accessible primarily through expensive private prescriptions, treatment opportunities may be determined more by income than by clinical need.
Generic and follow-on medicines could eventually help address some of these challenges by increasing competition and creating opportunities for lower prices.
The World Health Organization has highlighted several approaches that could contribute to more equitable access to GLP-1 therapies. These include generic production, pooled procurement, tiered pricing, voluntary licensing and local manufacturing.
For Kenya and other African countries, these discussions should begin early.
Governments, regulators, healthcare professionals and public health organisations need to consider how future market developments can translate into safe and affordable treatment options.
However, lower prices must never come at the expense of patient safety. All medicines must meet appropriate regulatory requirements, and patients must be protected from falsified, substandard or improperly distributed products.
Strong Regulation Must Accompany Expanded Access
The growing international demand for GLP-1 medicines has created opportunities for innovation, but it has also increased the risks associated with falsified and unregistered products.
Kenya has already experienced concerns around counterfeit semaglutide products. In 2024, the Pharmacy and Poisons Board issued a public alert following information about falsified Ozempic pens.
This demonstrates why regulatory oversight is essential as the market expands.
Patients need confidence that the medicines they receive are genuine, appropriately authorised and dispensed through legitimate healthcare channels.
Healthcare professionals also need accurate information on approved indications, prescribing requirements, contraindications and potential adverse effects.
For Stowelink Foundation, expanding access and strengthening regulation are complementary priorities. A responsible approach to obesity treatment must protect patients while ensuring that scientific advances can reach those who may benefit from them.
Making Obesity Treatment More Equitable in Kenya
Perhaps the most important question raised by the introduction of new obesity medicines is who will be able to access them.
A medicine can be available in a country without being affordable or accessible to most of its population.
This creates a risk of a two-tier healthcare system in which people with greater financial resources can access comprehensive obesity care while others are left with limited treatment options.
The WHO has highlighted affordability, supply constraints and health-system readiness as important barriers to the equitable global use of GLP-1 therapies.
Kenya must therefore consider affordability as part of its broader obesity policy agenda.
This includes examining how medicines could eventually be made available through public financing arrangements for appropriately selected patients, particularly those with significant health risks and related complications.
The introduction of new medicines also presents an opportunity to strengthen clinical pathways, improve health worker training and develop better systems for diagnosing and managing obesity.
Access should be guided by clinical need, available evidence and sustainable financing rather than the ability to pay privately.
Could Pooled Procurement Support Better Access?
One potential approach is pooled procurement.
When governments and public purchasing agencies negotiate for medicines collectively, they may have greater bargaining power than individual patients purchasing prescriptions independently.
Kenya could explore opportunities for strategic price negotiations and pooled purchasing as more evidence emerges and the market develops.
This would require careful assessment of the clinical benefits, cost-effectiveness, budget implications and health-system capacity associated with introducing GLP-1 therapies into publicly financed care.
It would also require decisions about which populations should be prioritised, based on clinical need and the expected health benefits of treatment.
The objective should not be to immediately make every available obesity medicine universally accessible without considering the financial implications.
Rather, Kenya should develop a sustainable framework that allows evidence-based treatment to reach people who need it most.
These discussions are increasingly important as countries consider how to integrate obesity prevention and management into their wider NCD and Universal Health Coverage strategies.
Integrating Obesity Care into Universal Health Coverage
The arrival of new obesity medicines raises a fundamental question about the place of obesity within Kenya’s Universal Health Coverage agenda.
If obesity is recognised as a chronic disease, its prevention, diagnosis and evidence-based treatment should be considered within the country’s broader approach to chronic disease care.
This does not mean that every available medicine must automatically be included in public financing. It means that obesity treatment should be evaluated through appropriate health technology assessment, clinical evidence, cost-effectiveness and budget-impact analysis.
Kenya’s evolving public health financing arrangements, including the Social Health Authority, could become part of future discussions on how to reduce out-of-pocket expenditure for clinically appropriate obesity care.
There may be opportunities to consider targeted coverage for people at higher risk, particularly where obesity is accompanied by serious complications and where treatment is expected to provide meaningful health benefits.
For Stowelink Foundation, the principle is clear: people living with obesity deserve access to appropriate healthcare, regardless of their socioeconomic circumstances.
The conversation about obesity treatment must therefore be part of the wider conversation about health equity and UHC in Kenya.
Medicines Are Important, But They Are Not the Entire Solution
While the introduction of GLP-1 therapies is an important development, medicines alone will not address the full burden of obesity.
Obesity is influenced by multiple interconnected factors, including food environments, physical activity opportunities, social and economic conditions, genetics, biological processes and commercial determinants of health.
Effective obesity management therefore requires a comprehensive response.
This includes:
- Population-level prevention and healthier food environments.
- Accurate public education and improved obesity literacy.
- Early identification and appropriate clinical assessment.
- Nutritional, behavioural and psychological support.
- Evidence-based pharmacological treatment where clinically appropriate.
- Access to specialist care and other treatment options when needed.
- Policies that address stigma and discrimination against people living with obesity.
These interventions should work together rather than compete for attention or resources.
Stowelink Foundation’s obesity advocacy recognises the importance of combining prevention, treatment literacy, community engagement and policy action.
Through initiatives such as Beyond the Scale Africa, the Foundation seeks to move the obesity conversation beyond body weight and individual responsibility towards a more comprehensive understanding of the disease and the systems that influence it.
Prevention and Treatment Must Move Together
There should be no false choice between preventing obesity and treating people who already live with the condition.
Kenya must continue addressing the wider drivers of obesity through healthier food environments, public education, improved access to physical activity and policies that support healthier communities.
At the same time, people already living with obesity deserve access to appropriate medical care.
Telling someone to change their lifestyle is not a substitute for clinical assessment, just as prescribing medication is not a substitute for comprehensive long-term support.
A stronger obesity response must recognise both responsibilities.
This means building health systems that can prevent obesity where possible, identify the disease early, manage associated complications, reduce stigma and provide access to appropriate treatment.
It also means listening to people with lived experience and ensuring their perspectives inform the policies and services designed to support them.
Building the Future of Obesity Care in Africa
The introduction of Wegovy and Ozempic in Kenya represents an important moment in the development of obesity and cardiometabolic care.
However, the long-term success of these medicines will not be measured by their market availability alone.
It will depend on whether Kenya can build a health system that translates scientific innovation into meaningful public health outcomes.
This will require responsible regulation, stronger clinical capacity, improved health literacy, greater competition, affordable treatment options and sustainable financing.
It will also require African countries to participate actively in shaping the global conversation on access to obesity medicines rather than simply adopting solutions developed elsewhere.
Ogweno Stephen’s participation in the Kenyan launch reflects Stowelink Foundation’s continued engagement in the evolving obesity policy and treatment landscape. Through its work in public health advocacy, NCD prevention, digital health and community engagement, the Foundation remains committed to advancing a more comprehensive and equitable response to obesity in Kenya and across Africa.
The arrival of new medicines is an important step. The next challenge is ensuring that the benefits of scientific progress are not limited to those who can afford them.
The future of obesity care in Kenya must be built around evidence, equity, patient safety and access.
